Imalumab ELISA Kit

Imalumab (as known as Bax69) is a novel recombinant, fully-human, monoclonal antibody (mAb) which was designed and developed to target the macrophage migration inhibitory factor, with potential immunomodulating, anti-inflammatory and antineoplastic activities. This drug was developed by Cytokine Pharma Sciences and Baxalta, which was purchased by Shire Pharmaceuticals. Phase I studies were completed in early 2016 and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. However, it is disappointing that there are no breakthrough and exciting clinical trial results for this monoclonal antibody. For example, a phase I/II trial in patients with malignant ascites was terminated in 2016 and Baxalta terminated a phase II trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA, Spain on 02 Jun 2017.

Imalumab

BAX069, BAX69, CAS: 1430205-07-4

Colorimetric

Quantitative

Plasma, Serum

0.31-5 μg/mL

80-120%

0.156 μg/ml

2-8 °C

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

For Research Use Only.